Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
10 02 2019
Historique:
pubmed: 14 12 2018
medline: 18 12 2019
entrez: 8 12 2018
Statut: ppublish

Résumé

Increasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. In this study, we assessed the safety and efficacy of a UCB graft that was expanded ex vivo in the presence of nicotinamide and transplanted after myeloablative conditioning as a stand-alone hematopoietic stem-cell graft. Thirty-six patients with hematologic malignancies underwent transplantation at 11 sites. The cumulative incidence of neutrophil engraftment at day 42 was 94%. Two patients experienced secondary graft failure attributable to viral infections. Hematopoietic recovery was compared with that observed in recipients of standard UCB transplantation as reported to the Center for International Blood and Marrow Transplant Research (n = 146). The median time to neutrophil recovery was 11.5 days (95% CI, 9 to 14 days) for recipients of nicotinamide-expanded UCB and 21 days (95% CI, 20 to 23 days) for the comparator ( P < .001). The median time to platelet recovery was 34 days (95% CI, 32 to 42 days) and 46 days (95% CI, 42 to 50 days) for the expanded and the comparator cohorts, respectively ( P < .001). The cumulative incidence of grade 2 to 4 acute graft-versus-host disease (GVHD) at day 100 was 44%, and grade 3 and 4 acute GVHD at day 100 was 11%. The cumulative incidence at 2 years of all chronic GVHD was 40%, and moderate/severe chronic GVHD was 10%. The 2-year cumulative incidences of nonrelapse mortality and relapse were 24% and 33%, respectively. The 2-year probabilities of overall and disease-free survival were 51% and 43%, respectively. UCB expanded ex vivo with nicotinamide shortens median neutrophil recovery by 9.5 days (95% CI, 7 to 12 days) and median platelet recovery by 12 days (95% CI, 3 to 16.5 days). This trial establishes feasibility, safety, and efficacy of an ex vivo expanded UCB unit as a stand-alone graft.

Identifiants

pubmed: 30523748
doi: 10.1200/JCO.18.00053
pmc: PMC6368416
doi:

Substances chimiques

Niacinamide 25X51I8RD4

Banques de données

ClinicalTrials.gov
['NCT01816230']

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-374

Subventions

Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Exp Hematol. 2012 Apr;40(4):342-55.e1
pubmed: 22198152
Biol Blood Marrow Transplant. 2016 Feb;22(2):359-370
pubmed: 26409243
Blood. 2005 Feb 1;105(3):1343-7
pubmed: 15466923
Science. 2014 Sep 19;345(6203):1509-12
pubmed: 25237102
J Clin Invest. 2014 Jul;124(7):3121-8
pubmed: 24911148
Cell Stem Cell. 2016 Jan 7;18(1):144-55
pubmed: 26669897
N Engl J Med. 2012 Dec 13;367(24):2305-15
pubmed: 23234514
Nat Med. 2010 Feb;16(2):232-6
pubmed: 20081862
Br J Haematol. 2015 Feb;168(3):405-12
pubmed: 25272241
Lancet Oncol. 2010 Jul;11(7):653-60
pubmed: 20558104
Biol Blood Marrow Transplant. 2017 Jul;23(7):1151-1157
pubmed: 28392378
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175
Ther Drug Monit. 2012 Oct;34(5):574-83
pubmed: 22972539
Biol Blood Marrow Transplant. 2018 Jul;24(7):1463-1470
pubmed: 29477778
Biol Blood Marrow Transplant. 2017 Nov;23(11):1949-1954
pubmed: 28729147
Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307
pubmed: 25797174
Blood. 2016 Mar 17;127(11):1502-8
pubmed: 26764356
Blood. 2012 Jul 26;120(4):905-13
pubmed: 22709687
N Engl J Med. 2014 Oct 30;371(18):1685-94
pubmed: 25354103

Auteurs

Mitchell E Horwitz (ME)

1 Duke University Medical Center, Durham, NC.

Stephen Wease (S)

2 Emmes Corporation, Rockville, MD.

Beth Blackwell (B)

2 Emmes Corporation, Rockville, MD.

David Valcarcel (D)

3 University Hospital Vall d'Hebron, Barcelona, Spain.

Francesco Frassoni (F)

4 Istituto Giannina Gaslini, Genoa, Italy.

Jaap Jan Boelens (JJ)

5 University Medical Center Utrecht, Utrecht, the Netherlands.

Stefan Nierkens (S)

5 University Medical Center Utrecht, Utrecht, the Netherlands.

Madan Jagasia (M)

6 Vanderbilt University Medical Center, Nashville, TN.

John E Wagner (JE)

7 University of Minnesota, Minneapolis, MN.

Jurgen Kuball (J)

5 University Medical Center Utrecht, Utrecht, the Netherlands.

Liang Piu Koh (LP)

8 National University Health System, Singapore.

Navneet S Majhail (NS)

9 Cleveland Clinic, Cleveland, OH.

Patrick J Stiff (PJ)

10 Loyola University Medical Center, Chicago, IL.

Rabi Hanna (R)

9 Cleveland Clinic, Cleveland, OH.

William Y K Hwang (WYK)

11 Singapore General Hospital, Singapore.

Joanne Kurtzberg (J)

1 Duke University Medical Center, Durham, NC.

Daniela Cilloni (D)

12 University of Turin, Turin, Italy.

Laurence S Freedman (LS)

13 Sheba Medical Center, Tel Hashomer, Israel.

Pau Montesinos (P)

14 Hospital Universitario y Politécnic de La Fe, Valencia, Spain.

Guillermo Sanz (G)

3 University Hospital Vall d'Hebron, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH